Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EVONIK INDUSTRIES AG

(EVK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Evonik and Stanford University sign research collaboration: Evonik to market and develop new drug delivery platform for mRNA and gene therapy

06/10/2021 | 07:04am EDT
  • Polymer-based drug delivery technology for targeted mRNA delivery
  • Stanford-licensed platform enables broader use of mRNA therapeutics
  • Expansion of Evonik's portfolio as system solutions partner for advanced drug delivery

Essen, Germany. Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). This polymer-based platform complements Evonik's existing portfolio of lipid-based drug delivery, including LNPs. Starting this month, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license and commercialize.

The new drug delivery technology of Evonik's Health Care business accelerates the portfolio shift of the life science division Nutrition & Care towards system solutions. Characterized by high growth prospects and above average margin potential, Nutrition & Care aims to increase the share of system solutions it offers from 20 percent today, to more than 50 percent by 2030.

'We are proud to collaborate with Stanford University and combine our innovative power in advanced drug delivery. Through this project we look forward to enabling the next generation of mRNA-based medicine,' says Dr. Thomas Riermeier, head of Evonik's Health Care business line.

The delivery of mRNA effectively and safely into the cell is one of the biggest challenges for expanding the use of mRNA therapeutics to promising fields such as cancer immunotherapy, protein replacement and gene editing. As a leading integrated development and manufacturing partner for advanced drug delivery, Evonik is well-positioned to address many of the pharma industry's unmet needs. Today, Evonik's accessible market for LNP-based delivery systems alone is estimated to be in excess of USD 5 billion by 2026.

'If we are to harness the full potential of mRNA therapeutics, we will need a toolbox of drug delivery technologies to target an expanded range of tissues and organs. Therefore, it is a great pleasure to collaborate with Stanford University and bring our expertise in advanced drug delivery to commercialize the new platform,' says Dr. Stefan Randl, Vice President of Research, Development & Innovation for Evonik Health Care.

Evonik will work together with Stanford University scientists to scale up the synthesis and formulation, and further develop this innovative technology for organ selective delivery based on a non-animal-derived, synthetic degradable polymer. As one of the few integrated development and manufacturing partners for gene therapies, Evonik aims to make this technology available in GMP quality (Good Manufacturing Practice) for use in clinical-stage developments and ultimately on a commercial scale.

The new polymer-based delivery platform, known as CART (Charge Altering Releasable Transporters), was developed by Professor Robert Waymouth, Professor Paul Wender and Professor Ronald Levy of Stanford University.

Across the entire pharmaceutical value chain, Evonik assumes a leading position as development and manufacturing partner. This includes pharmaceutical excipients such as lipids and custom lipids, formulation development and the manufacturing of clinical samples, as well as commercial drug products. The new polymer-based delivery system developed at Stanford University complements Evonik's technology platform for mRNA delivery.

Evonik recognized the potential of gene-based therapeutic approaches early in the emergence of these advances and made a targeted investment with the acquisition of Transferra Nanosciences in 2016. The Vancouver-based laboratories have a strong focus on parenteral drug formulation development using lipid nanoparticles and liposomes.

The portfolio was further expanded in 2020 with the acquisition of Wilshire Technologies, an American manufacturer of non-animal derived excipients for the pharmaceutical industry. This includes PhytoChol®, a non-animal derived cholesterol, used in many commercial parenteral pharmaceutical products.

Disclaimer

Evonik Industries AG published this content on 10 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 June 2021 11:03:06 UTC.


© Publicnow 2021
All news about EVONIK INDUSTRIES AG
07/26EVONIK INDUSTRIES AG : Preliminary announcement of the publication of financial ..
EQ
07/26DGAP-AFR : Evonik Industries AG: Preliminary announcement of the publication of ..
DJ
07/23EVONIK INDUSTRIES : presents its latest 'Living polyurethanes' solutions for imp..
AQ
07/22EVONIK INDUSTRIES : presents its latest “Living polyurethanes” solut..
PU
07/15EVONIK : Sell rating from Baader Bank
MD
07/14EVONIK INDUSTRIES : new emissions testing facility enables more sustainable poly..
PU
07/13EVONIK : Warburg Research reaffirms its Neutral rating
MD
07/09EVONIK - MILESTONE IN MARL : Minister President Armin Laschet inaugurates world'..
AQ
07/08MILESTONE IN MARL : Minister President Armin Laschet inaugurates world's largest..
PU
07/06EVONIK : DZ Bank remains Neutral
MD
More news
Financials
Sales 2021 13 366 M 15 862 M 15 862 M
Net income 2021 761 M 903 M 903 M
Net Debt 2021 2 621 M 3 110 M 3 110 M
P/E ratio 2021 18,1x
Yield 2021 3,96%
Capitalization 13 654 M 16 197 M 16 203 M
EV / Sales 2021 1,22x
EV / Sales 2022 1,16x
Nbr of Employees 32 745
Free-Float 41,1%
Chart EVONIK INDUSTRIES AG
Duration : Period :
Evonik Industries AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVONIK INDUSTRIES AG
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 29,30 €
Average target price 31,35 €
Spread / Average Target 6,99%
EPS Revisions
Managers and Directors
Christian Kullmann Chairman-Executive Board
Ute Wolf Chief Financial Officer
Bernd Tönjes Chairman-Supervisory Board
Andreas Fischer Chief Innovation Officer
Siegfried Luther Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVONIK INDUSTRIES AG9.82%16 197
BASF SE2.32%72 149
SHIN-ETSU CHEMICAL CO., LTD.-1.61%67 205
DUPONT DE NEMOURS, INC.5.54%39 937
ROYAL DSM N.V.20.70%34 430
PIDILITE INDUSTRIES LIMITED28.99%15 569